Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

City of Hope PANXEON Pancreatic Cancer Blood Test

Analysis based on 17 articles · First reported Sep 16, 2026 · Last updated Sep 17, 2026

Sentiment
15
Attention
2
Articles
17
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study highlights a potential breakthrough in early cancer detection, which could boost sentiment for diagnostic and biotech companies developing liquid biopsy platforms. Commercialization prospects remain uncertain pending further validation, but the involvement of Biocartis and its option on PANXEON points to potential upside for that company.

healthcare biotechnology diagnostics

Researchers led by City of Hope developed an investigational liquid biopsy called PANXEON that could detect pancreatic cancer at its earliest, potentially curable stages. The large international study, published in Nature Medicine, tested the blood test in nearly 1,800 patients across the United States, Europe and Asia. PANXEON analyzes three pancreatic cancer biomarkers - circulating microRNAs, exosomal microRNAs and the protein CA19-9 - and uses artificial intelligence to combine them into a single composite risk score. The test correctly identified stage 1 and 2 pancreatic cancer 87% of the time, with a false-positive rate of 3% in low-risk groups and 16% in high-risk groups. It also detected high-grade dysplasia, a precancerous condition often considered stage 0 pancreatic cancer, more than 64% of the time, potentially enabling intervention before invasive cancer develops. Senior author Ajay Goel, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope, said the findings represent progress toward finding pancreatic cancer before symptoms appear. The study was supported by the United States — National Institutes of Health, the United States — National Cancer Institute and the Italian Association for Cancer Research. Ajay Goel is a paid consultant to Biocartis, which holds an option to acquire the rights to PANXEON. City of Hope's affiliated organizations include the Translational Genomics Research Institute and AccessHope. Additional large-scale prospective studies are warranted to validate the test's utility.

95 City of Hope developed blood test
80 City of Hope tested blood test
60 Biocartis holds option
30 Italian Association for Cancer Research funded study City of Hope
ngo
City of Hope led the development of the PANXEON blood test and the international study, reinforcing its position as a leading cancer research and treatment organization.
Importance 100.0 Sentiment 30.0
per
Ajay Goel is the senior author of the study and chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope; he is also a paid consultant to Biocartis.
Importance 70.0 Sentiment 10.0
stock
Biocartis holds an option to acquire the rights to PANXEON, and Ajay Goel is a paid consultant to the company, giving it potential commercial upside if the test advances.
Importance 50.0 Sentiment 25.0
govactor
The United States — National Cancer Institute helped fund the study through grants supporting the research.
Importance 30.0 Sentiment 5.0
govactor
The United States — National Institutes of Health provided grant funding for the study through its United States — National Cancer Institute.
Importance 30.0 Sentiment 5.0
cnt
The United States was one of the regions where patients were tested, and City of Hope is a US-based institution.
Importance 20.0 Sentiment 5.0
ngo
The Italian Association for Cancer Research provided start-up grant funding for the study.
Importance 20.0 Sentiment 5.0
loc
Europe was one of the regions where patients were tested in the international study.
Importance 15.0 Sentiment 5.0
loc
Asia was one of the regions where patients were tested in the international study.
Importance 15.0 Sentiment 5.0
ngo
The Translational Genomics Research Institute is an affiliated organization of City of Hope mentioned in the context of its research network.
Importance 10.0 Sentiment 5.0
priv
AccessHope is an affiliated organization of City of Hope mentioned in the context of its care network.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.